deltatrials
Completed PHASE2 NCT00121030

Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy

An Open-Label, Randomized Phase 2 Study to Validate a Patient Satisfaction Questionnaire for Anemia Treatment in Patients With Gynecological Malignancies Treated With Darbepoetin Alfa or Recombinant Human Erythropoietin for Anemia Due to Chemotherapy

Sponsor: Amgen

Conditions Anemia Genital Neoplasms, Female Gynecological Malignancies
Interventions darbepoetin alfa recombinant human erythropoietin (rHuEPO)
Updated 5 times since 2017 Last updated: Dec 20, 2007 Started: Oct 31, 2002 Completion: Dec 31, 2003

A PHASE2 clinical study on Anemia and Genital Neoplasms, Female, this trial is completed. The trial is conducted by Amgen and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2

    First recorded

Oct 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.